Switching cisplatin to carboplatin in chemotherapy for metastatic penile cancer in a patient intolerant to cisplatin

Q4 Medicine

IJU Case Reports Pub Date : 2024-08-21 DOI:10.1002/iju5.12772

Keita Sekine, Takahito Suyama, Kazuki Takei, Hiroto Kato, Ken Wakai, Atsushi Okato, Kyokushin Hou, Kazuhiro Araki, Kazuto Yamazaki, Yukio Naya

{"title":"Switching cisplatin to carboplatin in chemotherapy for metastatic penile cancer in a patient intolerant to cisplatin","authors":"Keita Sekine, Takahito Suyama, Kazuki Takei, Hiroto Kato, Ken Wakai, Atsushi Okato, Kyokushin Hou, Kazuhiro Araki, Kazuto Yamazaki, Yukio Naya","doi":"10.1002/iju5.12772","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Cisplatin is currently the key drug in the chemotherapy regimen for metastatic penile cancer. There are few reports of alternative medicines for patients who cannot tolerate cisplatin. This report describes a case in which carboplatin was used instead.</p>\n </section>\n \n <section>\n \n <h3> Case presentation</h3>\n \n <p>The patient presented with a chief complaint of edema in the groin area. On close examination, penile cancer (cT2-3N3M0 stage IV) with pelvic lymph node metastasis was diagnosed. He was started on chemotherapy with cisplatin (50 mg/m<sup>2</sup> on days 1 and 2), paclitaxel (120 mg/m<sup>2</sup> on day 1), and 5-fluorouracil (1000 mg/m<sup>2</sup> on days 2–5), but he developed acute kidney failure on the 12th day, thought to be caused by cisplatin. Cisplatin was changed to carboplatin, and chemotherapy was continued. He has received nine courses of chemotherapy and is doing well.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>A case of penile cancer safely and effectively treated with chemotherapy using carboplatin was reported.</p>\n </section>\n </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"7 6","pages":"434-437"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531887/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJU Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iju5.12772","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Cisplatin is currently the key drug in the chemotherapy regimen for metastatic penile cancer. There are few reports of alternative medicines for patients who cannot tolerate cisplatin. This report describes a case in which carboplatin was used instead.

Case presentation

The patient presented with a chief complaint of edema in the groin area. On close examination, penile cancer (cT2-3N3M0 stage IV) with pelvic lymph node metastasis was diagnosed. He was started on chemotherapy with cisplatin (50 mg/m² on days 1 and 2), paclitaxel (120 mg/m² on day 1), and 5-fluorouracil (1000 mg/m² on days 2–5), but he developed acute kidney failure on the 12th day, thought to be caused by cisplatin. Cisplatin was changed to carboplatin, and chemotherapy was continued. He has received nine courses of chemotherapy and is doing well.

Conclusion

A case of penile cancer safely and effectively treated with chemotherapy using carboplatin was reported.

Abstract Image

查看原文本刊更多论文

不耐受顺铂的转移性阴茎癌患者在化疗中将顺铂改为卡铂。

简介顺铂是目前治疗转移性阴茎癌化疗方案中的主要药物。对于不能耐受顺铂的患者，很少有替代药物的报道。本报告描述了一个使用卡铂替代的病例：患者主诉腹股沟区水肿。经仔细检查，确诊为阴茎癌（cT2-3N3M0 IV 期）并伴有盆腔淋巴结转移。他开始接受顺铂（50 毫克/平方米，第 1 天和第 2 天）、紫杉醇（120 毫克/平方米，第 1 天）和 5-氟尿嘧啶（1000 毫克/平方米，第 2-5 天）化疗，但第 12 天出现急性肾衰竭，被认为是顺铂引起的。顺铂改为卡铂，化疗继续进行。他已经接受了九个疗程的化疗，目前情况良好：报告了一例使用卡铂化疗安全有效地治疗阴茎癌的病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊